Shan baoen

Sunbound is a clinical-stage biotechnology company focused on the discovery and development of next-generation small molecule therapeutics for oncology, with a particular emphasis on the RAS/MAPK signaling pathway. The company leverages its structure-based drug design platform to develop highly selective inhibitors targeting difficult-to-drug mutations such as KRAS G12D and KRAS G12V. Sunbound's lead programs are currently undergoing clinical evaluation for the treatment of advanced solid tumors, including non-small cell lung cancer and pancreatic cancer. By targeting specific oncogenic drivers, the company aims to provide more effective treatment options for patients with limited therapeutic alternatives.